-
Canan Schuman, PharmD/PhD
Posts
Amazon kicks off new role as diagnostics provider by making COVID test available online
Amazon has already changed the way we shop and filled our homes with “smart” gadgets, and now, the tech giant is looking to change the...
Provention Bio brought back down to earth as FDA panel narrowly backs diabetes prevention drug
Provention was flying high on Tuesday when an FDA advisory panel seemed to back the efficacy of its diabetes prevention drug, even after the agency...
NGM’s closely-watched NASH prospect flops, cutting shares in half and spurring R&D rethink
A phase 2b trial of NGM Biopharmaceuticals’ aldafermin in nonalcoholic steatohepatitis (NASH) has missed its primary endpoint, sending shares in the biotech tumbling. NGM has pulled...
DoorDash to stock COVID-19 test kits for home delivery
The people who bring you lunch can now also deliver a COVID-19 diagnostic test, as screening for the pandemic disease continues to become a more...
Lilly’s phase 2 Alzheimer’s win marred by missed secondaries, questions about clinical significance
Eli Lilly has shared full data from a phase 2 clinical trial it hailed as showing a “significant slowing of decline” in Alzheimer’s disease patients....
Donanemab in Early Alzheimer’s Disease
Abstract BACKGROUND A hallmark of Alzheimer’s disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ,...
Russia’s Sputnik V nabs first Twitter-verified vaccine handle, but is it PR or propaganda?
A blue check for Sputnik V—and a cautionary marketing tale for the pharma industry? The Russian-developed coronavirus vaccine nabbed verified status from Twitter last week,...
Woman of the Week: A 2020 Anthology
A full-year of amazing women leaders — 53 unique career journeys and 53 lessons in courage, perseverance, and strength. This e-publication features healthcare and life-science...
Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus
STAMFORD, Conn, and ST. GALLEN, Switzerland, March 08, 2021 (GLOBE NEWSWIRE) — Cara Therapeutics (Nasdaq:CARA) and Vifor Pharma today announced that the U.S. Food and Drug...
Takeda takes full control of drug for rare epilepsies
Takeda, the world’s largest developer of rare disease drugs, said Tuesday that it has reclaimed full rights to an experimental medicine being tested against uncommon...